Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
American Journal of Respiratory and Critical Care Medicine|May 6, 2010
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosisArmand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 24, 2020
Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimenPauline Lempens, Tom Decroo, Kya J M Aung, et al.Lancet (London, England)|December 19, 2006
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysisMohamed Abdel Aziz, Abigail Wright, Adalbert Laszlo, et al.Jac-Antimicrobial Resistance|April 13, 2022
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settingsArmand Van Deun, Valentin Bola, Rossin Lebeke, et al.Microbial Genomics|September 26, 2023
Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in BangladeshPauline Lempens, Armand Van Deun, Kya J M Aung, et al.Plos One|September 1, 2020
Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomesTom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, et al.Trials|September 10, 2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trialAndrew J Nunn, I D Rusen, Armand Van Deun, et al.Journal of Clinical Microbiology|December 8, 2004
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patientsIsdore Chola Shamputa, Leen Rigouts, Lovet Achale Eyongeta, et al.International Journal of Antimicrobial Agents|October 19, 2019
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forwardArmand Van Deun, Tom Decroo, Sabira Tahseen, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 7, 2023
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicinMahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, et al.Pageof 6